3.4.23.15: renin
This is an abbreviated version!
For detailed information about renin, go to the full flat file.
Word Map on EC 3.4.23.15
-
3.4.23.15
-
hypertension
-
aldosterone
-
arterial
-
urinary
-
cardiovascular
-
cardiac
-
antihypertensive
-
normotensive
-
gastric
-
glomerular
-
natriuretic
-
hemodynamic
-
systolic
-
diastolic
-
sympathetic
-
ras
-
angiotensin-converting
-
norepinephrine
-
output
-
adrenal
-
blocker
-
prostaglandin
-
ventricular
-
catecholamine
-
diuretic
-
creatinine
-
hg
-
electrolyte
-
placebo
-
vasopressin
-
captopril
-
vasodilator
-
cortisol
-
supine
-
intrarenal
-
renovascular
-
conscious
-
pressor
-
posture
-
acth
-
noradrenaline
-
losartan
-
hypotensive
-
mineralocorticoid
-
vasoconstriction
-
enalapril
-
furosemide
-
anp
-
medicine
-
macula
-
pharmacology
-
aceis
-
diagnostics
- 3.4.23.15
- hypertension
- aldosterone
- arterial
- urinary
- cardiovascular
- cardiac
-
antihypertensive
-
normotensive
- gastric
- glomerular
-
natriuretic
-
hemodynamic
-
systolic
-
diastolic
-
sympathetic
- ras
-
angiotensin-converting
- norepinephrine
- output
- adrenal
-
blocker
- prostaglandin
- ventricular
- catecholamine
-
diuretic
- creatinine
- hg
-
electrolyte
-
placebo
- vasopressin
- captopril
-
vasodilator
- cortisol
-
supine
-
intrarenal
-
renovascular
-
conscious
-
pressor
-
posture
- acth
- noradrenaline
- losartan
-
hypotensive
-
mineralocorticoid
-
vasoconstriction
- enalapril
- furosemide
- anp
- medicine
-
macula
- pharmacology
-
aceis
- diagnostics
Reaction
cleavage of Leu-/- bond in angiotensinogen to generate angiotensin I =
Synonyms
angiotensin-forming enzyme, angiotensinogenase, EC 3.4.4.15, EC 3.4.99.19, prorenin, REN, SVAP, SVAP A1, SVAP B1, SVAP B2, venom aspartic protease
ECTree
Advanced search results
Engineering
Engineering on EC 3.4.23.15 - renin
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
G149S/S150T
mutant enzyme shows lower specific activities than native renin. 50% loss in specific activity with 4-(4'-(dimethylaminophenylazo))-benzoyl-gamma-aminobutyryl-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS and 4-(4'-(dimethylaminophenylazo))-benzoyl-gamma-aminobutyryl-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS. Mutation has no effect on substrate specificity of canine renin
G149S/S150T/V286L
mutant enzyme shows lower specific activities than native renin
V286L
mutant enzyme shows lower specific activities than native renin
additional information
-
transgenic expression in Ren2 rat results in hypertension, insulin resistance, and cardiovascular damage. Treatment of young heterozygous male Ren2 and age-matched control rats with renin inhibitor aliskiren leads to significantly increased blood pressure, NADPH oxidase activity and subunit immunostaining, 3-nitrotyrosine, perivascular fibrosis, mitochondrial content and markers of activity in Ren2 rats. Both renin inhibition and blockade of the Ang I type receptor significantly attenuate cardiac functional and structural alterations
additional information
-
treatment of transgenic Ren2 rat results in systemic insulin resistance with decreased skeletal muscle insulin metabolic signaling and glucose uptake. Effects are associated with increased angiotensin II, mineralocorticoid receptor, angiotensin type I receptor, oxidative stress, and reduced tyrosine insulin receptor substrate phosphorylation, protein kinase B/(Akt) phosphorylation and GLUT-4 immunostaining